Pharmaceutical Cold Chain Packaging Industry Analysis in United States
>100 Views
August 06, 25
スライド概要
The pharmaceutical cold chain packaging industry in the United States is poised for significant expansion, with its market value projected to grow from USD 4.9 billion in 2025 to USD 13.8 billion by 2035. This represents a robust Compound Annual Growth Rate (CAGR) of 10.9% over the forecast period, driven by the critical need for temperature-controlled solutions to transport sensitive drugs, biologics, and vaccines.
Browse the Complete Report: https://www.futuremarketinsights.com/reports/pharmaceutical-cold-chain-packaging-industry-analysis-in-united-states
This growth is a direct response to the increasing development of high-value, temperature-sensitive pharmaceuticals and the need for validated logistics. The market, which accounts for a 4-6% share of the pharmaceutical packaging space, is a vital link in the drug supply chain. Recent strategic moves, such as Knipper Health’s acquisition of Thermo Fisher Scientific’s commercial sample management operations in Memphis, Tennessee, underscore the industry's focus on expanding cold chain infrastructure and leveraging strategic logistics hubs to meet rising demand.
Active Packaging and Biologics Drive Market Evolution
The market is not only expanding in size but also in technological sophistication. Active packaging is projected to be the leading segment, capturing a massive 79.8% share by 2035. These systems, with their integrated sensors and real-time monitoring capabilities, are essential for maintaining the efficacy of high-value biopharmaceuticals. The demand for these advanced solutions is primarily from biopharmaceutical companies, which are expected to account for a 50% market share in 2025 due to their heavy reliance on specialized cold chain packaging for transporting monoclonal antibodies, vaccines, and cell & gene therapies.
The most common temperature requirement is the refrigerated range (2°C - 8°C), which will hold a 45% market share in 2025. This temperature range is crucial for a wide array of biologics, vaccines, and injectables, necessitating packaging that can ensure precise thermal stability throughout the distribution network.
Dominant Products and Materials
In terms of product type, boxes are anticipated to hold a commanding 60% market share in 2025, valued for their versatility, affordability, and suitability for small- to medium-sized shipments. These designs are increasingly integrating advanced insulation materials and tamper-proof closures to meet stringent cold chain regulations.
The preferred material for insulation is Expanded Polystyrene (EPS), which is projected to dominate the substrate segment with a 35% market share in 2025. EPS is favored for its superior insulation capabilities, lightweight nature, and cost-effectiveness. Meanwhile, coolants, a critical component for maintaining temperature stability, are expected to lead their segment with a 65% share in 2025, driven by the use of gel packs, phase change materials (PCMs), and dry ice solutions.
Key Market Dynamics: Drivers and Restraints
The market is primarily driven by the expanding pipeline of advanced therapies and the increasingly strict regulatory standards from the FDA. These factors are compelling pharmaceutical companies to invest in validated cold chain systems that ensure drug safety and efficacy.
However, challenges remain. High costs associated with advanced packaging solutions, especially active systems, can be a barrier for smaller players. Environmental concerns are also a growing restraint, with regulations targeting polystyrene and plastic waste, which raises compliance costs. This dual pressure of cost and sustainability is pushing manufacturers to innovate in reusable and eco-friendly solutions.
Request Pharmaceutical Cold Chain Packaging Industry Analysis in United States Draft Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-22371
Future Market Insights is the premier provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Delaware, USA, and has its global delivery center in India. In addition to these, FMI also carries out business development and client engagement through its UK and UAE offices.
関連スライド
エシカルデータの潮流
tokoroten
82.6K
ステルス増税の見える化
安田 洋祐
19.3K
各ページのテキスト
Biologics and Active Packaging Propel U.S. Pharma Cold Chain Market Amid Strict FDA and Temperature Control Demands The U.S. pharmaceutical cold chain packaging market will grow to USD 13.8 billion by 2035, driven by a robust 10.9% CAGR and rising demand for advanced therapies. The pharmaceutical cold chain packaging industry in the United States is poised for significant expansion, with its market value projected to grow from USD 4.9 billion in 2025 to USD 13.8 billion by 2035. This represents a robust Compound Annual Growth Rate (CAGR) of 10.9% over the forecast period, driven by the critical need for temperature-controlled solutions to transport sensitive drugs, biologics, and vaccines. This growth is a direct response to the increasing development of high-value, temperature-sensitive pharmaceuticals and the need for validated logistics. The market, which accounts for a 4-6% share of the pharmaceutical packaging space, is a vital link in the drug supply chain. Recent strategic moves, such as Knipper Health’s acquisition of Thermo Fisher Scientific’s commercial sample management operations in Memphis, Tennessee, underscore the industry's focus on expanding cold chain infrastructure and leveraging strategic logistics hubs to meet rising demand. Active Packaging and Biologics Drive Market Evolution The market is not only expanding in size but also in technological sophistication. Active packaging is projected to be the leading segment, capturing a massive 79.8% share by 2035. These systems, with their integrated sensors and real-time monitoring capabilities, are essential for maintaining the efficacy of high-value biopharmaceuticals. The demand for these advanced solutions is primarily from biopharmaceutical companies, which are expected to account for a 50% market share in 2025 due to their heavy reliance on specialized cold chain packaging for transporting monoclonal antibodies, vaccines, and cell & gene therapies. The most common temperature requirement is the refrigerated range (2°C - 8°C), which will hold a 45% market share in 2025. This temperature range is crucial for a wide array of biologics, vaccines, and injectables, necessitating packaging that can ensure precise thermal stability throughout the distribution network. Dominant Products and Materials In terms of product type, boxes are anticipated to hold a commanding 60% market share in 2025, valued for their versatility, affordability, and suitability for small- to medium-sized shipments. These designs are increasingly integrating advanced insulation materials and tamper-proof closures to meet stringent cold chain regulations. The preferred material for insulation is Expanded Polystyrene (EPS), which is projected to dominate the substrate segment with a 35% market share in 2025. EPS is favored for its superior insulation capabilities, lightweight nature, and cost-effectiveness. Meanwhile, coolants, a critical component for maintaining temperature stability, are expected to lead their segment with a 65% share in 2025, driven by the use of gel packs, phase change materials (PCMs), and dry ice solutions. Regional Growth Hotspots in the U.S. The growth of the U.S. market is concentrated in key states with established biopharma hubs and robust logistics infrastructure. California leads the growth with a projected 5.9% CAGR from 2025 to 2035, driven by its concentration of biotech manufacturers and its emphasis on sustainable packaging innovation. Texas (5.5% CAGR) and New York (5.4% CAGR) follow closely, leveraging their
central locations and robust hospital networks, respectively. Other strategic states include Pennsylvania (5.2% CAGR) and Illinois (5.1% CAGR), which benefit from their historical pharmaceutical manufacturing base and status as major freight hubs. Key Market Dynamics: Drivers and Restraints The market is primarily driven by the expanding pipeline of advanced therapies and the increasingly strict regulatory standards from the FDA. These factors are compelling pharmaceutical companies to invest in validated cold chain systems that ensure drug safety and efficacy. However, challenges remain. High costs associated with advanced packaging solutions, especially active systems, can be a barrier for smaller players. Environmental concerns are also a growing restraint, with regulations targeting polystyrene and plastic waste, which raises compliance costs. This dual pressure of cost and sustainability is pushing manufacturers to innovate in reusable and eco-friendly solutions. Request Pharmaceutical Cold Chain Packaging Industry Analysis in United States Draft Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-22371 For more on their methodology and market coverage, visit! https://www.futuremarketinsights.com/about-us Competitive Landscape and Industry Outlook The market is moderately consolidated, with key players such as Sealed Air, CSafe, and PeliBioThermal Limited leading the way with comprehensive active packaging systems and logistics services. The industry is also seeing strategic consolidation, as evidenced by DHL Group's recent acquisition of CryoPDP in March 2025, a move designed to strengthen its life sciences logistics footprint. As the industry continues to evolve, strategic collaborations between packaging providers, logistics firms, and pharmaceutical companies will be crucial for developing scalable and sustainable cold chain solutions that can meet the complex demands of the modern pharmaceutical landscape. Explore Related Insights Pharmaceutical Tubes Market: https://www.futuremarketinsights.com/reports/pharmaceuticaltubes-market Pharmaceutical Caps and Closures Market: https://www.futuremarketinsights.com/reports/pharmaceutical-caps-and-closures-market Pharmaceutical Plastic Bottle Market: https://www.futuremarketinsights.com/reports/pharmaceutical-plastic-bottles-market Editor’s Note: This release is based exclusively on verified and factual market content derived from industry analysis by Future Market Insights. No AI-generated statistics or speculative data have been introduced. This press release highlights significant shifts in the pharmaceutical cold chain packaging industry analysis in United States, which is experiencing a pivotal change driven by consumer demand for healthier, more transparent products. About Future Market Insights (FMI)
- https://www.futuremarketinsights.com/reports/sample/rep-gb-22371
- https://www.futuremarketinsights.com/about-us
- https://www.futuremarketinsights.com/reports/pharmaceutical-tubes-market
- https://www.futuremarketinsights.com/reports/pharmaceutical-caps-and-closures-market
- https://www.futuremarketinsights.com/reports/pharmaceutical-plastic-bottles-market
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries. Join us as we commemorate 10 years of delivering trusted market insights. Reflecting on a decade of achievements, we continue to lead with integrity, innovation, and expertise. Contact Us: Future Market Insights Inc. Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware – 19713, USA T: +1-347-918-3531 For Sales Enquiries: [email protected] Website: https://www.futuremarketinsights.com LinkedIn| Twitter| Blogs | YouTube